Tiziana Life Sciences is trading 10.2% up at $0.98, with the move appearing driven mainly by biotech strength while broader indices decline.
- No new company-specific announcement was identified on September 23, 2026.
- The latest official update, dated September 21, reported completion of the last patient’s last visit in the Phase 2a INFORM-MS trial.